Parkside Financial Bank & Trust’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$89.8K Sell
2,302
-8
-0.3% -$258 0.01% 793
2026
Q1
$75.2K Buy
2,310
+7
+0.3% +$225 0.01% 801
2025
Q4
$81K Buy
2,303
+52
+2% +$1.84K 0.01% 775
2025
Q3
$59.2K Buy
2,251
+970
+76% +$28.9K ﹤0.01% 871
2025
Q2
$33.9K Buy
1,281
+3
+0.2% +$79 ﹤0.01% 1028
2025
Q1
$30.9K Buy
1,278
+404
+46% +$12.8K ﹤0.01% 988
2024
Q4
$35.2K Sell
874
-5
-0.6% -$285 ﹤0.01% 918
2024
Q3
$55.6K Buy
879
+5
+0.6% +$293 0.01% 746
2024
Q2
$46.3K Buy
874
+39
+5% +$2.56K 0.01% 774
2024
Q1
$68.5K Buy
835
+535
+178% +$23.8K 0.01% 640
2023
Q4
$5.58K Hold
300
– – ﹤0.01% 1279
2023
Q3
$3.32K Hold
300
– – ﹤0.01% 1510
2023
Q2
$4.86K Buy
300
+100
+50% +$2.1K ﹤0.01% 1386
2023
Q1
$3.33K Buy
+200
New +$2.07K ﹤0.01% 1514

Other funds holding VKTX

Parkside Financial Bank & Trust's VKTX Position: Q2 2026 in Review

Parkside Financial Bank & Trust reduced its Viking Therapeutics (VKTX) stake by 0.35% in Q2 2026, selling an estimated $258 and leaving 2,302 shares worth $89.8K. The position accounts for 0.01% of the portfolio, ranked #793.

Parkside Financial Bank & Trust first reported a position in VKTX in Q1 2023 and has held it in 14 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Parkside Financial Bank & Trust held 2,302 shares of Viking Therapeutics worth $89.8K as of Q2 2026.
  • Parkside Financial Bank & Trust sold 8 Viking Therapeutics shares in Q2 2026, an estimated $258.
  • Viking Therapeutics made up 0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #793 holding.
  • Parkside Financial Bank & Trust first reported a position in Viking Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.